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Abstract
Background: Detectable HIV-1 in body compartments can lead to transmission and antiretroviral resistance. Although sex
differences in viral shedding have been demonstrated, mechanisms and magnitude are unclear. We compared RNA levels in
blood, genital-secretions and saliva; and drug resistance in plasma and genital-secretions of men and women starting/
changing antiretroviral therapy (ART) in the AIDS Clinical Trials Group (ACTG) 5077 study.
Methods: Blood, saliva and genital-secretions (compartment fluids) were collected from HIV-infected adults ($13 years) at
14 United-States sites, who were initiating or changing ART with plasma viral load (VL) $2,000 copies/mL. VL testing was
performed on all compartment fluids and HIV resistance genotyping on plasma and genital-secretions. Spearman rank
correlations were used to evaluate concordance and Fisher’s and McNemar’s exact tests to compare VL between sexes and
among compartments.
Results: Samples were available for 143 subjects; 36% treated (23 men, 29 women) and 64% ‘untreated’ (40 men, 51
women). RNA detection was significantly more frequent in plasma (100%) than genital-secretions (57%) and saliva (64%)
(P,0.001). A higher proportion of men had genital shedding versus women (78% versus 41%), and RNA detection was more
frequent in saliva versus genital-secretions in women when adjusted for censoring at the limit of assay detection. Inter-
compartment fluid VL concordance was low in both sexes. In 22 (13 men, 9 women) paired plasma-genital-secretion
genotypes from treated subjects, most had detectable resistance in both plasma (77%) and genital-secretions (68%).
Resistance discordance was observed between compartments in 14% of subjects.
Conclusions: HIV shedding and drug resistance detection prior to initiation/change of ART in ACTG 5077 subjects differed
among tissues and between sexes, making the gold standard blood-plasma compartment assessment not fully
representative of HIV at other tissue sites. Mechanisms of potential sex-dependent tissue compartmentalization should
be further characterized to aid in optimizing treatment and prevention of HIV transmission.
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Introduction
Sexual transmission of the human immunodeficiency virus type-
1 (HIV) is directly related to HIV RNA level in the genital tract
[1,2,3]. Measurement of HIV RNA in the genital tract is not a
convenient clinical tool, and quantification of plasma HIV RNA is
used for clinical monitoring of HIV-infected subjects [4,5]. Plasma
HIV RNA correlates with viral detection in both genital fluid
[6,7,8,9] and saliva [10,11]. Although anti-retroviral therapy
(ART) effectively suppresses viral replication in all three compart-
ments [9,12,13,14], approximately10–40% of ART-treated sub-
jects have detectable HIV in the genital tract fluid but not in blood
plasma [6,7,8,9,15,16,17,18,19,20,21,22]. Such discordances sug-
gest a compartment-specific milieu for viral replication in blood
and non-blood compartments [23,24], which could lead to an
erroneous perception of genital viral suppression and persistent
potential for HIV transmission despite suppression of HIV in the
blood compartment.
HIV genital shedding is sporadic and may be associated with
age [6], co-infections [8], drug penetration [25,26], hormonal
levels, menstrual cycle and sex [8]. Although sex differences in
genital shedding have been consistently demonstrated, the
magnitude of the differences and mechanisms involved are not
well understood. Women may have lower plasma HIV RNA levels
compared to men with equivalent CD4 levels, whereas ART may
be more successful in suppressing genital HIV RNA in men than
women [26,27,28,29,30,31,32]. Differences in compartment-spe-
cific HIV RNA between ART-experienced men and women with
suppressed plasma virus imply that men and women may not
represent an immunologically or pharmacologically homogenous
group, which would have implications for treatment and disease
progression.
Viral replication in and shedding from the genital tract despite
ART and suppression of plasma HIV RNA may increase the risk
of developing drug resistance [33], [34]. Consequently, HIV
tropism and resistance patterns can differ markedly among
anatomic compartment sites [35,36,37,38,39], which indicates
local HIV replication in the genital tract [40,41]. We hypothesized
that underlying sex differences in genital viral replication (as
measured by HIV RNA level) may lead to sex differences in drug
resistance evolution and thus different viral drug resistance
patterns between blood and genital tract for different classes of
ART drugs.
We present study enrollment data from AIDS Clinical Trials
Group (ACTG) study 5077, an observational study designed to
examine inter-compartmental viral differences among HIV-
infected men and women to address this hypothesis. We compared
HIV levels in blood plasma, genital-secretions and saliva, and HIV
drug resistance in plasma and genital-secretions of men and
women who were either starting or changing ART.
Methods
Ethics Statement
Institutional review boards at the following participating
institutions approved the protocol: Johns Hopkins University,
Stanford University, San Francisco General Hospital, University
of Rochester, University of Southern California Medical Center,
University of Washington, University of Minnesota, Washington
University, The Ohio State University, Rush University Medical
Center, Miriam Hospital Rhode Island, University of North
Carolina, University of Hawaii at Manoa Leahi Hospital and the
Columbia University Presbyterian Medical Center. A written
informed consent was obtained from all participants. The ACTG
A5077 protocol did allow for informed consent from parent/legal
guardian on behalf of the minors/children. However, there were
no subjects enrolled who were ,18 years of age, so informed
consent was never obtained from parents/guardians on behalf of
the minors/children enrolled in our study.
Population and Sample Collection
ACTG study 5077 was a 96-week, multi-center longitudinal
study designed to evaluate viral shedding and antiretroviral drug
resistance characteristics by body compartment in men and
women (see Supplementary Protocol S1). The study was conduct-
ed between March 2001 and October 2002. Eligible HIV-infected
subjects age $13 years from 14 United-States ACTG sites were
offered enrollment if they: (1) were initiating or changing highly
active ART (HAART); (2) had plasma HIV RNA $2,000 copies/
mL within 60 days prior to study enrollment; and (3) were willing
to contribute samples of blood, saliva and genital-secretions.
HAART was defined as a minimum of three antiretroviral drugs
that included any of the following six combinations: (i) two
nucleoside reverse transcriptase inhibitors (NRTIs) and one non-
NRTI (NNRTI); (ii) two NRTIs and abacavir; (iii) two NRTIs and
a protease inhibitor (PI); (iv) two PIs and an NNRTI; (v) two PIs
and a NRTI; or (vi) a NRTI, a NNRTI and a PI. Subjects were
excluded if they: (1) were pregnant; (2) had active opportunistic
infections (OIs), intercurrent illnesses, or other infections within 14
days prior to study enrollment; (3) had used any immunomodu-
latory agents within 14 days prior to study enrollment; or (4) had
any active immunization within 14 days prior to study enrollment.
Upon obtaining informed consent, clinic records were reviewed
for demographic information, history of HIV-related diagnoses
and AIDS-defining events, and ART history. Samples obtained
included blood, saliva, and genital-secretions. Specimens for
plasma HIV RNA levels and blood CD4+ cell counts were
obtained at entry and every 8 weeks thereafter for 96 weeks, as
well as at ‘‘virological failure,’’ which was defined as a confirmed
detection of $200 RNA copies/mL $16 weeks after starting or
changing ART. Compartmental fluid samples were obtained at
baseline, weeks 16, 48 and 96, and at ‘‘virological failure’’.
Saliva samples were obtained by expectoration into a 50-mL
conical centrifuge tube that was then frozen at 220uC within 2
hours of collection and stored on site at 280uC. Genital-secretions
for men consisted of seminal fluid collected via masturbation into a
sterile urine container, following 48-hours of abstinence. For
women, a pelvic examination was performed with collection of
three endocervical wicks (Sno-strips, Chauvin Pharmaceuticals
Limited, Essex, UK) [42]. Following a one to three minute wicking
period, the three wicks were removed, cut at the wick neck, placed
into 500 mL of NASBA Buffer solution (bioMerieux, Durham,
NC) and stored at 270uC. Women refrained from any kind of
sexual activity, douching or insertion of intravaginal products for
at least 48 hours prior to the collection of cervical specimens.
Cervical vaginal lavage (CVL) samples were collected by bathing
the cervix and ectocervix three-times with the same 10-mL of
phosphate-buffered-saline solution, which was then aspirated and
placed into a sterile 50-mL conical centrifuge tube. If signs or
symptoms of a genitourinary tract infection were noted, the subject
was evaluated, diagnosed and treated appropriately for at least 14
days and the infection considered resolved prior to genital-
secretion sampling. Subjects were not screened for asymptomatic
genital tract infections.
Genital specimens were processed within four hours of
collection and stored on site at 270uC prior to shipment on dry
ice to the ACTG central specimen repository (Biomedical
Research Institute (BRI), Rockville, MD USA) for long-term
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storage at 280uC. Frozen specimen aliquots were shipped to Johns
Hopkins University for HIV-1 RNA testing of blood plasma; to the
University of North Carolina for HIV RNA testing of semen and
saliva; and to the University of Washington ACTG Virology
Specialty Laboratory for HIV RNA quantification in cervical and
cervicovaginal fluids.
Laboratory Testing
HIV RNA was measured in blood plasma using RT-PCR
(Monitor version 1.5 (Roche Molecular) at a central laboratory.
HIV RNA was extracted into NucliSens extraction buffer from
saliva, seminal plasma or endocervical wicks and quantified using
published NucliSens (bioMerieux; saliva, seminal plasma) or real-
time RT-PCR assay methods [43,44,45,46]. The lower limits of
viral RNA detection were 50 copies/mL in blood plasma, 400
copies/mL in saliva, 400 copies/mL in semen plasma, 1,500
copies/mL in cervical Sno-strip fluid, and 75 copies/mL in CVL
fluid. The difference in the lower limit of detection between
seminal plasma and endocervical wicks was due to the require-
ment for sample dilution during specimen processing. The intra-
assay standard deviation was ,0.3 log10 RNA copies/mL of
seminal plasma from men, based on blinded testing [44]. A similar
intra-assay standard deviation was obtained for HIV-1 RNA
measurements from endocervical wicks and CVL, but these data
were generated from a previous assay validation for a longitudinal
genital tract HIV-1 shedding study of women [43,47].
HIV RNA from blood plasma and genital-secretions was
sequenced through the gag/pol genes protease and reverse
transcriptase regions at four ACTG virology laboratories that
participated in the NIAID-DAIDS-sponsored Virology Quality
Assurance (VQA) Program for HIV genotyping, including
Vanderbilt University (VU), University of North Carolina
(UNC), Stanford University (SU) and University of Washington
(UW). Paired blood and genital-secretion samples were run at the
same labs. Three different methods were used for genotyping
including TRUGENE HIV Genotyping Kit for RT-PCR
amplification and OpenGene System for sequencing (Siemens
Health Care) at VU and UNC; Invitrogen RT-PCR and
sequencing at Stanford University, and an in-house independently
validated assay for amplification and ABI 377 sequencing at UW.
The raw nucleotide sequence data were sent for analyses to the
Frontier Science & Technology Research Foundation (FSTRF)
data management center and to the Statistical Data Analysis
Center (SDAC) of the ACTG. Quality control of sequence data
was performed via phylogenetic analysis using PHYLIP 3.65. The
sequences have been deposited in Genbank under accession
numbers KJ468189–KJ468232.
Statistical Analysis
Patients were allocated into ‘untreated’ and treated groups for
analysis. ‘Untreated’ for this study was defined as having had no
prior ART exposure ever or for at least 90 days or more (off
treatment) prior to study enrollment, according to patient self-
report. HIV RNA level was assessed in both the ‘untreated’ and
treated patient groups, while drug resistance was evaluated only in
the treated group, which was expected to have resistant and/or
wild-type viruses.
Spearman rank correlations were used to evaluate concordance
between compartment sites. Fisher’s exact test was used to
compare HIV RNA level between men and women in saliva
and genital tract, and Wilcoxon rank-sum tests were used to
compare HIV RNA levels in the blood between men and women.
Figure 1. Flowchart of Enrolled Subjects and Available Samples by Sex. White boxes represent the subset of subjects with genotypes
available from both blood and genital secretions. The ‘untreated’ group refers to subjects who were either antiretroviral drug naı̈ve or who had been
off ART for $90 days.
doi:10.1371/journal.pone.0093537.g001
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HIV RNA detection was compared between compartments using
McNemar’s test. Patients were considered to be ‘‘shedders’’ if HIV
RNA was detectable in the compartment fluid. Left-censored HIV
RNA levels (i.e., measurements below assay limits) were analyzed
as the lowest rank. For women with both Sno-strip and CVL
samples available, Sno-strip results were analyzed because they
were more precise [47].
Drug resistance mutations were assessed at protease and reverse
transcriptase resistance-related positions in plasma and genital
tissues in men and women according to the Stanford HIV
Sequence Database tools (http://hivdb.stanford.edu; accessed 4/
16/2013). Sequence analyses were restricted to treated subjects
(i.e. those taking ART at or within 90 days of study enrollment)
since resistance mutations can fade in the absence of antiretroviral
drug pressure [48]. Resistance was measured as overall (i.e. any
resistance mutation), drug class, and specific mutations. Plasma-
genital tract concordance of resistance mutations was assessed and
compared between sexes. Resistance discordance was defined as at
least one drug resistance amino acid mutation that occurred in one
compartment and not the other within a plasma and genital-
secretion sequence pair. Amino acid mixtures including a
resistance mutation were classified as mutant.
Results
Patient Characteristics
Between March 2001 and October 2002, 173 patients (87 men
and 86 women) were enrolled (Figure 1). Of these, 143 (63 men
and 80 women) had available paired blood plasma and genital
compartment VL measurements, and were included in the
analysis. Fourteen men and five women chose not to provide
genital samples. Ten seminal, 11 Sno-strips and one CVL samples
were not successfully evaluated because of insufficient specimen
volume or unsuccessful PCR amplification. Among these 143
patients, 52 (36%) were treated (23 men, 29 women), and 91 (64%)
were ‘untreated’ (40 men, 51 women). Of the ‘untreated’, 19 men
and 17 women were treatment naı̈ve and the remainders were not
exposed to ART within 90 days prior to study enrollment. Of
women, 83% of treated and 90% of ‘untreated’ had Sno-strips
available in addition to CVL. Paired saliva samples were available
for 88% of patients, 89% of women and 87% of men.
Table 1. Characteristics of Enrolled Subjects at Study Enrollment by Sex and History of ART.
Male Female All
n = 63 n = 80 n = 143
Treated Untreated .90 days Treated Untreated .90 days Treated Untreated .90 days
n = 23 n = 40 n = 29 n = 51 n = 52 n = 91
Age, median (IQR) years 44 (41,47) 38 (35,44) 42 (37,46) 39 (35,45) 43 (40,47) 39 (35,44)
Number of drugs ever taken, median (IQR)
Total 8 (5,9) 2 (0,5) 7 (5,9) 4 (0,7) 7 (5,9) 3 (0,6)
NRTIs 4 (3,5) 1 (0,3) 4 (3,5) 3 (0,4) 4 (3,5) 2 (0,4)
NNRTIs 1 (0,1) 0 (0,1) 1 (1,1) 0 (0,1) 1 (1,1) 0 (0,1)
PIs 2 (1,4) 0 (0,2) 2 (1,4) 1 (0,2) 2 (1,4) 1 (0,2)
Regimen before enrollment (n)
NRTI, NNRTI, & PI 4 – 4 – 8 –
NRTI & PI
(No NNRTI)
3 – 5 – 8 –
NRTI & NNRTI
(No PI)
1 – 3 – 4 –
Other 5 – 3 – 8 –
None 10 – 14 – 24 –
Years since first ARV, 7.3 0.8 5.8 4.4 6.2 3.2
use median (IQR) years (4.6, 11.5) (0, 5.4) (3.8, 7.8) (0, 6.6) (4.1, 9.5) (0, 6.4)
CD4 cell count/mL, 185 241 210 183 197 216
median (IQR) (108, 314) (121, 334) (76, 401) (87, 284) (96, 361) (93, 294)
Plasma HIV RNA, 4.6 4.8 4.4 4.8 4.6 4.8
median log10 c/mL (IQR) (4.4, 5.1) (4.5, 5.6) (4.1, 5.1) (4.3, 5.4) (4.1, 5.1) (4.4, 5.5)
Number of Subjects with Samples Collected
Plasma 23 40 29 51 52 91
Semen 23 40 – – 23 40
Sno-strip – – 24 46 24 46
CVL – – 29 51 29 51
Saliva 19 36 25 46 44 82
Footnote: n, number; IQR, interquartile range; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease
inhibitor; ARV, antiretroviral; CVL, cervical vaginal lavage.
doi:10.1371/journal.pone.0093537.t001
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Patient characteristics at study enrollment are shown in Table 1
by sex and treatment history. Median age was 43 years in treated
patients and 39 in ‘untreated’. Treated patients had taken a
median of seven different antiretroviral drugs prior to enrollment,
whereas ‘untreated’ patients were exposed to a median of three
(per definition, .90 days prior to study enrollment). Among
treated subjects, the most common regimens at study enrollment
included NRTIs and PIs (29%) or NRTIs, NNRTIs and PIs
(29%). Treated subjects had a median of 6.2 years since first ART
use, and ‘untreated’ subjects had a median of 3.2 years. Median
CD4 count at enrollment was 197 cells/mL in treated subjects and
216 cells/mL in ‘untreated’. There were no significant differences
between men and women in HIV RNA level or CD4 count,
overall or within the treated and ‘untreated’ groups (p.0.1).
Viral RNA Level in Blood, Genital Compartments and
Saliva
Figure 2 demonstrates HIV RNA detection and concordance by
sex, anatomic site, and treatment status. Overall viral RNA
detection in the study cohort was 100% in blood plasma (inclusion
criterion), 57% in genital-secretions (82/143) and 64% in saliva
(81/126). Detection of HIV RNA in plasma was significantly more
frequent than in genital-secretions and saliva (p,0.001). Sex-
specific viral detection for the genital fluid was 78% (49/63) in
men and 41% in women [14% (11/80) in CVL and 46% (32/70)
in Sno-strip specimens] and for saliva, 62% (34/55) in men and
66% (47/71) in women. Men had significantly more frequent
genital HIV RNA detection compared to women, a trend that
held in both treated (70% vs. 38%, p = 0.03) and ‘untreated’ (83%
vs. 43%, p,0.001) subjects. Women had HIV detected more
frequently in saliva compared to genital-secretions (66% vs. 41%,
p = 0.01).
Median plasma HIV RNA level in treated, ‘untreated’ and
overall was 4.6, 4.8 and 4.7 log10 RNA copies/mL in men and 4.4,
4.8 and 4.7 log10 RNA copies/mL in women, respectively
(p = 0.50 comparing all). Paired HIV RNA values were lower in
all non-plasma compartments compared to plasma (Figure 2).
Concordance of HIV RNA levels between blood plasma and
genital-secretions was low and not significant in men (r = 0.26,
0.21 and 0.24 for treated, ‘untreated’ and overall; Figure 3a), and
low but reaching statistical significance (p,0.05) for ‘untreated’
and overall in women (r = 0.20, 0.37 and 0.32 for treated,
‘untreated’ and overall; Figure 3b). For both men and women,
detection of HIV RNA in genital fluids was infrequent when the
plasma viral RNA level was ,4.0 RNA log10 copies/mL.
HIV RNA level concordance between plasma and saliva was
low for both men (r = 0.00, 0.38 and 0.25 for treated, ‘untreated’
and overall) and women (r = 0.38, 0.14 and 0.30 for treated,
‘untreated’ and overall), although significant for ‘untreated’ men
and women overall (p,0.05).
Drug Resistance
Paired plasma and genital-secretion genotypes were available
for 22 treated subjects, 13 men and 9 women (2/9 CVL and 7/
9 Sno Strips) (Figure 1). All sequences were HIV-1 subtype B, and
sequences from different anatomic compartments within the same
patient clustered together with high (.90%) bootstrap support.
Most subjects had detectable drug resistance mutations in
plasma (77%) and genital-secretions (68%); see Figure 4. More
subjects had NRTI-associated mutations (64% in plasma, 59% in
genital-secretions) than NNRTI (36% in plasma, 36% in genital-
secretions) or PI (32% in plasma, 27% in genital-secretions)-
associated mutations.
The inter-compartment concordance of drug resistant muta-
tions varied by drug class for both men and women. In men
Figure 2. HIV RNA level in Anatomic Compartments of Enrolled Men and Women. Vertical bars represent percent of subjects with
detectable viral load at study enrollment by anatomic compartment fluid and treatment status. The ‘untreated’ group refers to subjects who were
either antiretroviral drug naı̈ve or who had been off ART for $90 days.
doi:10.1371/journal.pone.0093537.g002
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(Figure 5a), mutations occurred in $3 subjects at NRTI-associated
positions 41, 67, 70, 215 and 219 in plasma, and 67, 70 and 219 in
semen; at NNRTI-associated position 103 in both plasma and
semen; and at PI-associated positions 10, 71 and 90 in both plasma
and semen. In women (Figure 5b), mutations occurred in $2
subjects at NRTI-associated positions 70, 184, 215 and 219 in
plasma, and 67, 70, 184 and 219 in genital-secretions; at NNRTI-
associated position 103 in both plasma and genital-secretions; and
at PI-associated position 10 in plasma.
Based on paired plasma and genital genotypes, 7/13 (54%) men
and 5/9 (56%) women demonstrated complete concordance in
positions showing drug resistance. In the seven subjects (4 men, 3
women) with discordant NRTI-associated mutations in plasma
versus genital-secretions, five had NRTI mutations in plasma not
seen in genital-secretions; two had NRTI mutations in genital-
secretions that were not detected in plasma. In the three subjects
(all men) with discordant NNRTI-associated mutations, one had
NNRTI mutations in plasma not seen in genital-secretions; two
had NNRTI mutations in genital-secretions that were not detected
in plasma. In the three subjects (1 man, 2 women) with discordant
PI-associated mutations, two had PI mutations in plasma not seen
in genital-secretions; one had PI mutations in genital-secretions
that were not detected in plasma.
In plasma, 36% (8/22) of subjects had resistance to one ART
class (38% of men, 33% of women); 27% (6/22) to two classes
(23% of men, 33% of women); and 14% (3/22) to three classes
(15% of men, 11% of women). In genital-secretions, 27% (6/22) of
subjects had resistance to one ART class (31% of men, 22% of
women); 27% (6/22) to two classes (31% of men, 22% of women);
and 14% (3/22) to three classes (15% of men, 11% of women).
The classes of ART with detectable resistance were the same in
plasma and genital-secretions for the majority of subjects (86%,
19/22); class resistance differed for one man (NNRTI resistance in
plasma vs. NNRTI and PI resistance in genital-secretions) and two
women (PI resistance in plasma vs. no resistance detected in
genital-secretions; NRTI and PI resistance in plasma vs. no
resistance detected in genital-secretions).
Discussion
We present inter-compartment HIV RNA detection and drug
resistance comparisons among HIV-infected men and women with
detectable plasma HIV RNA levels, who were initiating or
changing ART in ACTG study 5077. This study, which was done
in the US, enrolled equal numbers of women and men who
contributed significant number of blood, genital tract and salivary
samples. Many studies have enrolled only men or women and few
had the ability to make significant comparisons in genital tract
HIV RNA level by sex. In this study population, genital-secretion
(57%) and saliva (64%) viral detection was high, and men had
significantly greater detection of genital tract HIV RNA than did
women. In this study population, both men and women continued
to shed HIV RNA in the genital tract, thus increasing their
potential risk of sexually transmitting HIV. Since a plasma HIV
RNA of $2,000 copies/mL was an inclusion criterion, we were
not able to assess genital tract HIV shedding among those with
undetectable plasma viral levels. However, 21% of men and 24%
of women had genital tract HIV RNA greater than plasma HIV
RNA, including two men with a 2 log10 higher genital tract HIV
RNA than plasma [49,50]. When adjusted for the left-censoring
associated with different lower limits of detection for each of the
three samples assayed, concordance of HIV RNA levels between
plasma and non-plasma compartments was low in both sexes,
though higher in women.
HIV RNA results from this study support prior reports of
frequent discordance between blood and genital compartments,
although previous studies found more frequent detection of HIV
Figure 3. Association of Blood-Plasma and Genital Tract Fluid
HIV RNA by Sex. Scatterplots demonstrating the Spearman correla-
tions between blood and seminal plasma (A) and between blood and
SnoStrip (B) viral load. Filled symbols represent those with paired blood
and genital secretion genotypes; individuals with detectable drug
resistance mutations in either blood or genital secretions are marked
with an ‘x’.
doi:10.1371/journal.pone.0093537.g003
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in genital fluids compared to plasma, which may be in part due to
the blood plasma HIV RNA $2000 copies/mL screening
criterion in our study [10,11,33,35,51]. As inclusion criteria in
this study required detectable HIV RNA in plasma, previous
results could not be directly compared. Our study also supports
prior findings of differences in genital detection of HIV and
blood/non-blood compartmental concordance across sexes
[26,27,28,29,30,31]. However, results presented here indicate
higher genital HIV RNA levels in men than women, which does
not concur with one study in which men were more likely than
women to suppress genital VL [52]. Baeten et al. and others have
shown a direct relationship between the risks of HIV sexual
transmission and genital tract HIV RNA level [2]. Regardless of
the differences, HIV RNA level discordances imply that plasma
HIV RNA is not fully representative of genital and other
compartmental viral shedding.
HIV shedding in saliva was at higher frequency than genital
HIV shedding for women but was similar for men. Though not
considered a common mode of transmission [53,54], and despite
reports of antiviral activity of salivary components [55], relatively
higher HIV RNA in saliva of women may represent unique, sex-
dependent transmission risk associated with saliva; the transmis-
sion risk associated with oral-sex is low and still controversial. Such
findings may have implications for HIV transmission in special
circumstances, such as high viral replication and mandates further
investigation [46,56,57,58].
Most treated study subjects had drug resistance to ART
detected in both plasma and genital compartments, most likely
because this patient group had been somewhat adherent as
opposed to completely non-adherent to ART. Our study is
consistent with prior findings of compartmental differences in drug
resistance [40,41] in subjects on failing regimens. Concordance of
resistance mutations between plasma and genital-secretions in
both men and women varies widely across studies, ranging up to
84% [59]. Although most drug resistance mutations were
identified in genital-secretions and plasma, some inter-compart-
mental discordance was observed. This might reflect variable drug
penetration into different tissues, which may differ between men
and women; e.g., the effect of the menstrual cycle on genital viral
shedding [43,60]. Importantly, discordance implies that plasma
cannot be considered fully representative of drug resistance
patterns in other anatomic sites. Resistance mutations in genital
fluids and not in plasma were seen in our study in 14% of men and
women, including mutations like RT D67N and K103N; and
protease I84V, which could go unnoticed and subsequently be
transmitted. Since most of this discordance occurred among
subjects not on ART, it is possible that off-drug decay rates may
have differed between compartments and contributed to this
discordance. Based on the satisfactory participation of all four
resistance-testing laboratories in an external quality assurance
program for HIV genotypic drug resistance, inter-laboratory
variation is less likely to explain this discordance. Nevertheless,
better assays and further research are needed to examine drug
resistance evolution between blood and non-plasma compartments
[61].
This study has seven key limitations. First, treatment history was
provided by self-report and may not be accurate or complete. This
disallows the reliable determination of regimen-based resistance
profiles. Second, small sample size did not allow for robust effect
estimates, particularly in subjects with genotypes available. Third,
different methods in different laboratories with varying detection
capabilities in the respective compartment fluids because of
Figure 4. Antiretroviral Drug Resistance in Plasma and Genital Tract Fluid by Drug Class in Enrolled Men and Women. Vertical bars
represent percent of subjects with resistance mutations, overall and by drug class (NRTI: nucleoside reverse transcriptase inhibitor, NNRTI: non-
nucleoside reverse transcriptase inhibitor, PI: protease inhibitor).
doi:10.1371/journal.pone.0093537.g004
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Figure 5. HIV Drug Resistance Mutations in Paired Plasma and Genital Tract Fluid of Enrolled Men (A) and Women (B). Vertical bars
represent number of subjects with specific mutations in plasma (dark bars) and genital tract (gray bars). The X-axis depicts nucleoside reverse
transcriptase inhibitor (NRTI; positions 41–219), non-nucleoside reverse transcriptase inhibitor (NNRTI; positions 98–238) and protease inhibitor (PI;
positions 10–90) associated positions.
doi:10.1371/journal.pone.0093537.g005
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dilution effects were used to measure HIV RNA, which increases
difficulty in interpretation of comparisons, especially comparisons
between male and female genital-secretions, even when all the
assays were independently validated and externally quality
controlled. Fourth, the cohort was not homogeneous in terms of
treatment history, which can affect viral RNA levels and resistance
concordance among the anatomic sites. Fifth, co-infections such as
cytomegalovirus (CMV) were not evaluated. CMV in particular
has been associated with HIV shedding in the male genital tract
[62] and local CMV reactivation could have been a contributing
factor to disproportionately high genital viral RNA levels in a
subset of study participants with low CD4 cell counts and greater
immune suppression. Sixth, the input viral template was not
quantified or standardized for genotyping, which may have limited
the detection of mutant viruses to a variable degree within and
between anatomic sites. Finally, detectable plasma HIV RNA $
2000 copies/mL was part of the inclusion criteria, and so this
analysis does not include subjects with lower or undetectable
plasma HIV RNA but detectable genital fluid or saliva HIV RNA.
Despite these limitations, further insight into the relationship of
viral levels between blood, saliva and genital fluids of men and
women was achieved using the A5077 clinical trial design.
In summary, our results highlight that plasma HIV RNA may
not always reflect genital tract HIV shedding or resistance
patterns, with differences in detected resistance in a minority of
subjects. Importantly, a subset of treatment-experienced men and
women continue to have genital tract HIV shedding implying
continued risk of HIV transmission and potentially transmission of
drug resistant virus. Further investigation is needed to determine
possible mechanisms for these differences [61], particularly with
newer ART regimens that were not available at the time of our
study. For example, these mechanisms may be sex specific and
related to specific genital tract hormonal and other environment
influences including the genital tract microbiome. Although
assessment of plasma genotyping in blood can provide accurate
surrogate information about drug resistance in genital-secretions,
some discordances do occur bi-directionally between the blood
and genital compartments, potentially due to tissue site-specific
replication, providing insight into the mechanism of compartmen-
talization of HIV. In contradistinction to our study hypothesis,
there was predominately resistance concordance between the
blood and genital tract for both men and women. Nevertheless,
further understanding of resistance discordance may aid in
treatment and prevention of HIV transmission. The prevalence
of drug resistant virus in genital-secretions will pose a significant
challenge to pre-exposure prophylaxis as well as treatment as
prevention strategies.
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